Women offered less invasive or intensive treatment than men with the same conditions

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-18T05:54:14.478Z • Permanent link

Women are being shortchanged when it comes to medical treatment, according to a new study that highlights the stark disparities in care between men and women. A team of researchers at the University of California, Los Angeles (UCLA) analyzed data from over 1.5 million patients and found that women were less likely to receive invasive or intensive treatments, such as surgery or strong painkillers, for the same medical conditions as men. The study's lead author, Dr. Sophia Patel, notes that these disparities are not just a matter of personal preference, but rather a result of systemic biases in the healthcare system.

The study's findings were published in the journal PLOS Medicine and were based on data from the Kaiser Permanente health insurance organization, which serves over 12 million members in the United States. The researchers analyzed data from patients who were diagnosed with conditions such as heart disease, cancer, and stroke, and found that women were less likely to receive treatments that were considered standard of care for men. For example, women with heart disease were less likely to receive angioplasty or coronary artery bypass grafting, while women with cancer were less likely to receive chemotherapy or radiation therapy.

Dr. Patel emphasizes that these disparities are not limited to the United States and are a global problem. "We've looked at data from other countries, and the pattern is the same," she says. "Women are being treated differently than men, and it's not just a matter of cultural or societal differences. It's a fundamental issue with the way we deliver healthcare." The study's findings have sparked widespread concern among healthcare professionals and advocacy groups, who are calling for greater transparency and accountability in the treatment of women's health.

The study's findings have significant implications for the healthcare industry, particularly in terms of patient outcomes and satisfaction. Women are more likely to experience poor health outcomes and higher mortality rates than men, and these disparities are often due to inadequate or delayed treatment. The study's results suggest that the healthcare system is failing to provide women with the same level of care as men, and that this is having serious consequences for women's health.

The study's findings also have implications for the development of new treatments and therapies. If women are less likely to receive treatments that are considered standard of care, then these treatments may not be as effective for women as they are for men. This could have significant consequences for the development of new treatments and therapies, particularly in the areas of cancer and cardiovascular disease. Companies such as Pfizer and Johnson & Johnson, which are major players in the development of new treatments, may need to rethink their approaches to women's health and ensure that their treatments are safe and effective for women.

The study's findings are also likely to have significant implications for research communities and policymakers. The study's results highlight the need for greater transparency and accountability in the treatment of women's health, and for policymakers to take a more active role in addressing these disparities. Research communities, particularly in the areas of women's health and healthcare disparities, will need to rethink their approaches to data collection and analysis, and ensure that their methods are more inclusive and representative of women's experiences.